Q1 FY27 Results: Revenue up 21%, PAT up 28% YoY; Final Dividend Recommended
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 3.2 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Prevest Denpro's board approved Q1 FY27 unaudited results (standalone and consolidated). Consolidated revenue rose about 21% YoY to Rs. 19.07 cr, PAT grew about 28% to Rs. 5.64 cr, EPS Rs. 4.70. Standalone revenue up about 24% to Rs. 19.44 cr, PAT up about 25% to Rs. 5.78 cr. Board also recommended 10 percent final dividend (Rs. 1 per share) for FY26, subject to AGM approval. Labour Code implementation added Rs. 2.28 cr to employee costs in the quarter.
Strong YoY growth in revenue and profits with dividend declared. Positive quarter for shareholders, though Labour Code raised employee costs.